Treatment of severe hypertension during pregnancy : we still do not know what the best option is
Intracranial hemorrhage and stroke are primary causes of maternal mortality in pregnancies affected by hypertensive disorders. As such antihypertensive therapy plays a crucial role in the management of severe hypertension. However, the target level to achieve the best outcome for both - mother and fetus - is still unclear. Moreover, given the lack of well-designed randomized controlled trials with standardized key outcomes, the current choice of antihypertensive medications depends rather on clinicians' preference. Furthermore, data on long-term outcomes of offspring is not available. Therefore, there is an urgent need for randomized trials comparing different anti-hypertensive options to address efficacy and safety questions.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:39 |
|---|---|
| Enthalten in: |
Hypertension in pregnancy - 39(2020), 1 vom: 14. Feb., Seite 25-32 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Wertaschnigg, Dagmar [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antihypertensive Agents |
|---|
| Anmerkungen: |
Date Completed 02.11.2020 Date Revised 02.11.2020 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/10641955.2019.1708383 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM30480536X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM30480536X | ||
| 003 | DE-627 | ||
| 005 | 20231225115753.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/10641955.2019.1708383 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1015.xml |
| 035 | |a (DE-627)NLM30480536X | ||
| 035 | |a (NLM)31880480 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Wertaschnigg, Dagmar |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Treatment of severe hypertension during pregnancy |b we still do not know what the best option is |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 02.11.2020 | ||
| 500 | |a Date Revised 02.11.2020 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Intracranial hemorrhage and stroke are primary causes of maternal mortality in pregnancies affected by hypertensive disorders. As such antihypertensive therapy plays a crucial role in the management of severe hypertension. However, the target level to achieve the best outcome for both - mother and fetus - is still unclear. Moreover, given the lack of well-designed randomized controlled trials with standardized key outcomes, the current choice of antihypertensive medications depends rather on clinicians' preference. Furthermore, data on long-term outcomes of offspring is not available. Therefore, there is an urgent need for randomized trials comparing different anti-hypertensive options to address efficacy and safety questions | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Severe hypertension in pregnancy | |
| 650 | 4 | |a key outcome parameters | |
| 650 | 4 | |a maternal and perinatal morbidity | |
| 650 | 4 | |a pre-eclampsia | |
| 650 | 4 | |a target blood pressure | |
| 650 | 7 | |a Antihypertensive Agents |2 NLM | |
| 700 | 1 | |a Wang, Rui |e verfasserin |4 aut | |
| 700 | 1 | |a Reddy, Maya |e verfasserin |4 aut | |
| 700 | 1 | |a Costa, Fabricio Da Silva |e verfasserin |4 aut | |
| 700 | 1 | |a Mol, Ben Willem J |e verfasserin |4 aut | |
| 700 | 1 | |a Rolnik, Daniel L |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Hypertension in pregnancy |d 1997 |g 39(2020), 1 vom: 14. Feb., Seite 25-32 |w (DE-627)NLM093649401 |x 1525-6065 |7 nnns |
| 773 | 1 | 8 | |g volume:39 |g year:2020 |g number:1 |g day:14 |g month:02 |g pages:25-32 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/10641955.2019.1708383 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 39 |j 2020 |e 1 |b 14 |c 02 |h 25-32 | ||